NT-501: An ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 5, 2008, Pages 506-515

  Emerich, D F ^a   Thanos, C G ^b  

^a InCytu Inc   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR RECEPTOR; POLYMER;

CATARACT; CELL LINE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG METABOLISM; EYE INFLAMMATION; FIBROSIS; GENE DELIVERY SYSTEM; HUMAN; IMPLANT; LOW DRUG DOSE; NONHUMAN; NT 501; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; REVIEW;

CELL LINE; CELLS, IMMOBILIZED; CILIARY NEUROTROPHIC FACTOR; CLINICAL TRIALS AS TOPIC; HUMANS; MACULAR DEGENERATION; POLYMERS; PROSTHESES AND IMPLANTS; RETINITIS PIGMENTOSA;

EID: 53249147453     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. 199972 Polymer encapsulated cell lines genetically engineered to release ciliary neurotrophic factor can slow down progressive motor neuronopathy in the mouse. Sagot Y, Tan SA, Baetge E, Schmalbruch H, Kato AC, Aebischer P EUR J NEUROSCI 1995 7 6 1313-1322
2. 257558 Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, Chu Y, McDermott P, Baetge EE, Kordower JH NATURE 1997 386 6623 395-399
3. 265110 Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Aebischer P, Pochon NA, Heyd B, Deglon N, Joseph JM, Zurn AD, Baetge EE, Hammang JP, Goddard M, Lysaght M, Kaplin F et al HUM GENE THER 1996 7 7 851-860
4. 299885 Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Emerich DF, Cain CK, Greco C, Saydoff JA, Hu ZY, Liu H, Lindner MD CELL TRANSPLANT 1997 6 3 249-266
5. 435819 Neurotech signs license agreement with Amgen. Neurotech SA PRESS RELEASE 2002 January 14
6. 465673 Encapsulated cell based intraocular delivery of CNTF reduces inherited retinal degeneration in an rcd1 dog model. Tao W, Sherman S, O'Rourke P, Bell W, Stabila P, Dean B, Kauper K, Budz V, Goddard M INVEST OPHTHALMOL VIS SCI 2001 42 4 S173 • This study demonstrated that NT-501 can prevent the loss of photoreceptors to maintain visual acuity in a dog model of retinal degeneration.
7. 481695 Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Tao W, Wen R, Goddard MB, Sherman SD, O'Rourke PJ, Stabila PF, Bell WJ, Dean BJ, Kauper KA, Budz VA, Tsiaras WG et al INVEST OPHTHALMOL VIS SCI 2002 43 10 3292-3298
8. 512544 VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA J CELL PHYSIOL 2003 195 2 241-248
9. 577778 Pegaptanib for neovascular age-related macular degeneration. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR N ENGL J MED 2004 351 27 2805-2816
10. 598598 Positive phase I data for Neurotech's NT-501 encapsulated cell delivery of ciliary neurotrophic factor to eyes of patients with retinitis pigmentosa. Neurotech SA PRESS RELEASE 2005 May 01
11. 632396 Ciliary neurotrophic factor (CNTF) phase 1 trial for human retinal degenerations. Sieving PA, Caruso RC, Tao W, Thompson DJS, Fullmer KR, Coleman HR, Bush RA ABSTR SOC NEUROSCI 2005 35 Abs 45.14
12. 643519 Neurotech starts phase II AMD trial of intraocular implant. Neurotech SA PRESS RELEASE 2006 January 05
13. 655622 Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Sieving A, Caruso C, Tao W, Coleman R, Thompson JS, Fullmer R, Bush A PROC NATL ACAD SCI USA 2006 103 10 3896-3901 •• This study provided the first clinical safety and tolerability data in patients with retinitis pigmentosa receiving implants of NT-501 into the vitreous.
14. 692670 Prevalence of age-related macular degeneration in the United States. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J ARCH OPHTHALMOL 2004 122 4 564-572
15. 785132 NCT00447993: A study of encapsulated cell technology (ECT) implant for patients with late stage retinitis pigmentosa. CLINICALTRIALS.GOV 2007 March 14
16. 785139 NCT00447980: A study of encapsulated cell technology (ECT) implant for participants with early stage retinitis pigmentosa. CLINICALTRIALS.GOV 2007 March 14
17. 785487 Long-term performance and viability of genetically engineered retinal pigment epithelial (RPE) cells secreting CNTF encapsulated in hollow fiber membrane devices. McGovern C, Sherman S, Mateus S, Bishop A, Dold M, Stabila P, Lydon J, Lee A, Tao W, Tente W INVEST OPHTHALMOL VIS SCI 2005 46 Abs 473
18. 785488 Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Thanos CG, Bell WJ, O'Rourke P, Kauper K, Sherman S, Stabila P, Tao W TISSUE ENG 2004 10 11-12 1617-1622 •• This study provided a comprehensive analysis of the sustained secretion of CNTF from encapsulated cells implanted into the vitreous of rabbits.
19. 785489 Improved growth control of encapsulated cells by modification of scaffold geometry. Tao W, Bintz B, Thanos C, McGovern C, Lee A, Lydon J, Kauper K INVEST OPHTHALMOL VIS SCI 2004 45 Suppl 2 Abs 5069
20. 785490 Evaluation of a novel encapsulated cell technology device designed for intraocular delivery of CNTF. Kauper KA, Chauvin P, Bintz FB, Thanos FC, O'Rourke P, Lydon J, Lee A, Tao W INVEST OPHTHALMOL VIS SCI 2004 45 Suppl 2 Abs 5063
21. 785491 Sustained delivery of hCNTF to rabbit vitreous humor by two polymer encapsulated cell lines in the NT-502 device. Tente W, O'Rourke P, Sherman S, Kauper K, McGovern C, Matteus S, Dean B, Tao W, Thanos C INVEST OPHTHALMOL VIS SCI 2004 45 Suppl 2 Abs 5049
22. 785492 Microcarrier cell culture for precise dose regulation and control of cell proliferation in the NT-501 intraocular device. Thomas CG, Dean B, Kauper K, Tao W INVEST OPHTHALMOL VIS SCI 2004 45 Suppl 2 Abs 5045
23. 848143 Neurotech completes enrollment in NT-501 phase II/III retinal disease studies. Neurotech Pharmaceuticals Inc PRESS RELEASE 2007 November 06
24. 890201 Phase I study of ciliary neurotrophic factor (CNF) delivered by intravitreal implant of encapsulated cell technology (ECT) device in patients with retinitis pigmentosa. Sieving PA, Caruso RC, Tao W, Thompson DJS, Fullmer KR, Coleman HR, Bush RA INVEST OPHTHALMOL VIS SCI 2005 46 Suppl S 531
25. 890202 Encapsulated cell based delivery of CNTF to the vitreous comparing a polysulfone and a polyethersulfone membrane formulated device. Kauper KA, Sherman S, Heatherton P, Litvak D, McGovern C, Mateus S, Lydon J, Lee A, Wenthold R, Tao W INVEST OPHTHALMOL VIS SCI 2005 46 Suppl Abs 474
26. 890206 Identification and evaluation of optimal environment for maintenance of encapsulated CNTF secreting cell lines prior to intraocular implantation. Kauper KA, Sherman S, O'Rourke P, Bell W, Stabilia P, Goddard M, Tao W INVEST OPHTHALMOL VIS SCI 2002 43 Abs 2304
27. 890209 Safety, tolerability and toxicology evaluation of encapsulated cell based intraocular delivery of CNTF in minipigs. Goddard MB, O'Rourke P, Sherman S, Bell W, Lim A, McGuire S, Budz V, Geltzer A, Tao W INVEST OPHTHALMOL VIS SCI 2002 43 Abs 2306
28. 890214 The effect of ambient storage conditions on the recombinant protein secretion rates and cell viability of polymer encapsulated human retinal pigmented epithelial cells genetically engineered to secrete ciliary neurotrophic factor. Tente W, Thanos CG, Kauper K, Sherman S, Bell W, Provencal R, Tao W INVEST OPHTHALMOL VIS SCI 2003 44 Abs 4435
29. 890218 In vitro evaluation of polymer encapsulated CNTF secreting mammalian cell lines over the course of a ten month period. Kauper KA, Sherman S, Stabilia P, Mills J, Bell B, Thanos C, Tao W INVEST OPHTHALMOL VIS SCI 2003 44 Abs 4443
30. 890220 Alkaline hydrolysis of poly (ethylene terepthalate) yarn for improving cell attachment and long-term viability in the NT-501 intraocular device. Thanos CG, Kauper K, Sherman S, Bell W, Provencal R, Chauvin P, Tao W INVEST OPHTHALMOL VIS SCI 2003 44 Abs 4459
31. 913238 Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ MOL VISION 2008 14 997-1005
32. 913310 Neovascular age-related macular degeneration: Potential therapies. Chappelow AV, Kaiser PK DRUGS 2008 68 8 1029-1036
33. 917700 Long term in vitro stability of CNTF secreting NT-501 implants. McGovern C, Kauper K, Sherman S, Mateus S, Stabila P, Lee A, Bouchard B, Tao W INVEST OPHTHALMOL VIS SCI 2008 49 Abs 1828
34. 917701 Effect of membrane porosity on CNTF delivery using the NT-501 micronized device. McGovern C, Kauper K, Sherman S, Mateus S, Stabila P, Lydon J, Lee A, Dean B, Tente W, Tao W INVEST OPHTHALMOL VIS SCI 2007 48 Abs 628
35. 917711 Characterization of CNTF release from ECT devices with long-term incubations. McGovern C, Sherman S, Stabila P, Lydon J, Lee A, Dean B, Kauper K, Litvak D, Tente W, Tao W INVEST OPHTHALMOL VIS SCI 2006 47 Abs 5124
36. 917713 Characterization of CNTF secreting mammalian cell lines for encapsulated cell therapy. Tao W, Stabila PF, Lee A, Dean BJ, Lim A, Bell WJ INVEST OPHTHALMOL VIS SCI 2003 44 Abs 4436
37. 917714 Construction, characterization and safety testing of CNTF secreting mammalian cell lines for encapsulated cell therapy. Tao W, Stabila P, Dean B, Bell W INVEST OPHTHALMOL VIS SCI 2002 43 Abs 2312
38. 917723 Effect of encapsulated cell based intraocular delivery of ciliary neurotrophic factor (CNTF) on rabbit eyes: Electroretinogram, histological and funduscopic observations. Lei B, Tao W, Bush RA, Sieving PA INVEST OPHTHALMOL VIS SCI 2002 43 Abs 1783
39. 917853 Long-term protection of cones by CNTF secreting implants in transgenic rats carrying the rhodopsin mutation S334ter. Wen R, Li Y, Tao W, Zhao L, Kauper K, Stabila P, LaVail MM, Laties AM INVEST OPHTHALMOL VIS SCI 2008 49 Abs 2078
40. 917854 Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor (CNTF) in normal rabbit: Dose dependent effects on ERG and retinal histology. Bush RA, Lei B, Tao W, Raz D, Chan CC, Cox TA, Santos-Muffley M, Sieving PA INVEST OPHTHALMOL VIS SCI 2004 45 Abs 856
41. 917856 Delivery of encapsulated cell technology (ECT) device implants using a small gauge needle. Kauper KA, Stabila P, Mills J, Lee A, Litvak D, Lydon J, Heatherton P, Tao W INVEST OPHTHALMOL VIS SCI 2006 47 Abs 5118
42. 917858 Safety and pharmacokinetics of an injectable encapsulated cell technology implant. Kauper KA, Heatherton P, Lydon J, Mills J, Lee A, McGovern C, Bock M, Tao W INVEST OPHTHALMOL VIS SCI 2007 48 Abs 627
43. 917860 Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: Dose-dependent effects on ERG and retinal histology. Bush RA, Lei B, Tao W, Raz D, Chan CC, Cox TA, Santos-Muffley M, Sieving PA INVEST OPHTHALMOL VIS SCI 2004 45 7 2420-2430
44. 917862 Development of a micronized encapsulated cell technology (ECT) device capable of producing therapeutic proteins to the vitreous. Tao W, Stabilia P, Litvak D, Mills J, Lee A, McGovern C, Lydon J, Wenthold R, Kauper K INVEST OPHTHALMOL VIS SCI 2005 46 Abs 497
45. 917929 CNTF induces dose-dependent alterations in retinal morphology in normal and rcd-1 canine retina. Zeiss CJ, Allore HG, Towle V, Tao W EXP EYE RES 2006 82 3 395-404
46. 918124 Regulation of rod phototransduction machinery by ciliary neurotrophic factor. Wen R, Song Y, Kjellstrom S, Tanikawa A, Liu Y, Li Y, Zhao L, Bush RA, Laties AM, Sieving PA J NEUROSCI 2006 26 52 13523-13530
47. 918871 Transplantation of neural tissue in polymer capsules. Aebischer P, Winn SR, Galletti PM BRAIN RES 1988 448 2 364-368
48. 918873 Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium. Martin G, Schlunck G, Hansen LL, Agostini HT GRAEFES ARCH CLIN EXP OPHTHALMOL 2004 242 4 321-326
49. 918879 Intraocular CNTF reduces vision in normal rats in a dose-dependent manner. McGill TJ, Prusky GT, Douglas RM, Yasumura D, Matthes MT, Nune G, Donohue-Rolfe K, Yang H, Niculescu D, Hauswirth WW, LaVail MM et al INVEST OPHTHALMOL VIS SCI 2007 48 12 5756-5766
50. 931252 Hereditary retinal disease. Goodwin P CURR OPIN OPHTHALMOL 2008 19 3 255-262
51. 931305 Age-related macular degeneration. Jager RD, Mieler WF, Miller JW N ENGL J MED 2008 358 24 2606-2617
52. 931309 Age-related macular degeneration - emerging pathogenetic and therapeutic concepts. Gehrs KM, Anderson DH, Johnson LV, Hageman GS ANN MED 2006 38 7 450-471
53. 931310 Neovascular age-related macular degeneration: Potential therapies. Chappelow AV, Kaiser PK DRUGS 2008 68 8 1029-1036
54. 931773 NCT00063765: Evaluation of safety of ciliary neurotrophic factor implants in the eye. CLINICALTRIALS.GOV 2008
55. 931786 NCT00447954: A study of an encapsulated cell technology (ECT) implant for patients with atrophic macular degeneration. CLINICALTRIALS.GOV 2008
56. 931788 NCT00277134: A phase II study of implants of encapsulated human NTC-201 cells releasing ciliary neurotrophic factor (CNTF) in participants with visual acuity impairment associated with atrophic macular degeneration. CLINICALTRIALS.GOV 2008
57. 932535 Intrathecal implants of microencapsulated xenogenic chromaffin cells provide a long-term source of analgesic substances. Jeon Y, Kwak K, Kim S, Kim Y, Lim J, Baek W TRANSPLANT PROC 2006 38 9 3061-3065
58. 935806 Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Ferrara N, Damico L, Shams N, Lowman H, Kim R RETINA 2006 26 8 859-870
59. 935807 Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Levy J, Shneck M, Rosen S, Klemperer I, Rand D, Weinstein O, Pitchkhadze A, Belfair N, Lifshitz T INT OPHTHALMOL 2008 DOI:10.1007/s10792-008-9243-1
60. 935808 Delivery of neurotrophic factors and therapeutic proteins for retinal diseases. Thanos C, Emerich D EXPERT OPIN BIOL THER 2005 5 11 1443-1452
61. 940092 Neurotech's NT-501 receives US Fast Track status for retinitis and dry AMD. Neurotech Pharmaceuticals Inc PRESS RELEASE 2008 September 03
62. 940974 Ho A, Brown G, McNamara JA, Recchia F, Regillo CD, Vander JF: RETINA: COLOR ATLAS & SYNOPSIS OF CLINICAL OPHTHALMOLOGY The McGraw-Hill Companies, New York, NY, USA 2003